NASH biotech, Metacrine (MTCR) to raise $85M by offering 6.5M shares at a price range of $12 – $14.
Metacrine is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal, or GI, diseases. Most advanced program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases.
https://seekingalpha.com/news/3612642-metacrine-sets-ipo-terms
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.